NCT03958799View on ClinicalTrials.gov

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions
Tetanus Immunisation (Healthy Volunteers)Diphtheria Immunisation (Healthy Volunteers)Pertussis Immunisation (Healthy Volunteers)
Interventions
BIOLOGICAL

Investigational Tdap vaccine Formulation B

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Investigational Tdap vaccine Formulation C

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Investigational Tdap vaccine Formulation A

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Investigational Tdap vaccine Formulation D

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Licensed Tdap vaccine

Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Trial Locations (5)

B3K 6R8

Investigational Site Number 1240006, Halifax

H9H 4Y6

Investigational Site Number 1240009, Pierrefonds

G1N 4V3

Investigational Site Number 1240004, Québec

J1L 0H8

Investigational Site Number 1240005, Sherbrooke

B2N 1L2

Investigational Site Number 1240003, Truro

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03958799 - A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada | Biotech Hunter | Biotech Hunter